In prostate cancer an increased number of holoclones is associated with the expression of the putative stem cell markers CD44, integrin α2β1, CD133 [14], [17], PSAlo expression [23] and aldehyde dehydrogenase 1 (ALDH) activity [20]. Here, CD44 is linked to prostate cancer.